These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 24899199)

  • 1. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
    Cheung PK; Shahid A; Dong W; Lepik KJ; Montaner JSG; Brockman MA; Brumme ZL; Brumme CJ
    J Antimicrob Chemother; 2022 Mar; 77(4):979-988. PubMed ID: 35061879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
    Kagan RM; Dunn KJ; Snell GP; Nettles RE; Kaufman HW
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):698-709. PubMed ID: 31169022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 subtype F integrase polymorphisms external to the catalytic core domain contribute to severe loss of replication capacity in context of the integrase inhibitor resistance mutation Q148H.
    Aulicino PC; Momin Z; Rozenszajn M; Monzon A; Arazi-Caillaud S; Bologna R; Mangano A; Kimata JT
    J Antimicrob Chemother; 2022 Sep; 77(10):2793-2802. PubMed ID: 35897124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
    AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.
    Delelis O; Thierry S; Subra F; Simon F; Malet I; Alloui C; Sayon S; Calvez V; Deprez E; Marcelin AG; Tchertanov L; Mouscadet JF
    Antimicrob Agents Chemother; 2010 Jan; 54(1):491-501. PubMed ID: 19901095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
    Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
    Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
    Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Wainberg MA
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2087-94. PubMed ID: 12069959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.
    Barnard JP; Huber KD; Sluis-Cremer N
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
    Chitongo R; Obasa AE; Mikasi SG; Jacobs GB; Cloete R
    PLoS One; 2020; 15(5):e0223464. PubMed ID: 32379830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.
    Boyer PL; Melody K; Smith SJ; Dunn LL; Kline C; Fischer DK; Dwivedi R; Clark P; Hughes SH; Ambrose Z
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.
    Selhorst P; Vazquez AC; Terrazas-Aranda K; Michiels J; Vereecken K; Heyndrickx L; Weber J; Quiñones-Mateu ME; Ariën KK; Vanham G
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1403-13. PubMed ID: 21282453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes.
    Quercia R; Dam E; Perez-Bercoff D; Clavel F
    J Virol; 2009 Oct; 83(19):10245-9. PubMed ID: 19605484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
    Wildum S; Paulsen D; Thede K; Ruebsamen-Schaeff H; Zimmermann H
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5320-9. PubMed ID: 23959304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes.
    DeStefano JJ
    Biochemistry; 2019 Apr; 58(16):2176-2187. PubMed ID: 30900874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors.
    Yang LL; Li Q; Zhou LB; Chen SQ
    Int J Antimicrob Agents; 2019 Nov; 54(5):547-555. PubMed ID: 31398480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
    Paredes R; Tzou PL; van Zyl G; Barrow G; Camacho R; Carmona S; Grant PM; Gupta RK; Hamers RL; Harrigan PR; Jordan MR; Kantor R; Katzenstein DA; Kuritzkes DR; Maldarelli F; Otelea D; Wallis CL; Schapiro JM; Shafer RW
    PLoS One; 2017; 12(7):e0181357. PubMed ID: 28753637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.